Pfizer Inc. (0Q1N.L)
| Previous close | 50.83 |
| Open | 50.82 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 51.34 - 51.43 |
| 52-week range | 31.93 - 54.90 |
| Volume | |
| Avg. volume | 231,797 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 30 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.30 |
- Yahoo Finance Video
Big Tech earnings, jobs report, Fed decision: What to Watch
Big Tech earnings are on deck next week as Microsoft (MSFT), Meta Platforms (META), Apple (AAPL), and Amazon (AMZN) are scheduled to report their second quarter results. Jobs data for July are due out on Friday, August 2, making for a busy week for the US economy as Federal Reserve officials meet for their July FOMC meeting. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Luke Carberry Mogan.
Business WireEuropean Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
NEW YORK, July 25, 2024--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX® (fidanacogene elaparvovec), a gene therapy for the treatment of severe and moderately severe hemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74. DURVEQTIX is designed to enable people living with hemophilia B to produce
Business WirePfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
NEW YORK, July 24, 2024--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A.
